Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06349837

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Led by Sichuan University · Updated on 2026-05-01

24

Participants Needed

1

Research Sites

241 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard therapy. At least 9 participants will be enrolled in this study.

CONDITIONS

Official Title

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. Be willing and able to provide written informed consent/assent for the trial.
  2. Be ≥18 years of age on day of signing informed consent.
  3. Patients with histologically or cytologically confirmed stage IV solid tumours.
  4. Be willing to undergo repeat biopsy of tumor lesions according to the study protocol.
  5. Patients who have failed the standard therapy, or who are unsuitable for standard treatment, or refuse chemotherapy.
  6. At least one measurable lesion according to RECIST 1.1. A lesion that has previously received radiotherapy can be considered a target lesion only if this lesion is clearly progressed after radiotherapy.
  7. The target lesions (irradiated lesions) are > 5cm in in diameter
  8. ECOG 0-2.
  9. Life expectancy of > 3 months.
  10. Subjects should agree to use an adequate method of contraception.
Not Eligible

You will not qualify if you...

  1. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis and/or spinal cord compression, etc.
  2. With oncologic emergencies that require immediate treatment
  3. EGFR/ALK/ROS-1 mutation or mutation status unknown.
  4. Has evidence of interstitial lung disease or active and/or non-infectious pneumonitis (drug-induced pneumonia, radiation-induced pneumonia, etc.) requiring steroid therapy.
  5. History of pulmonary fibrosis, pulmonary hypertension, severe irreversible airway obstruction disease
  6. Patients with peripheral neuropathy.
  7. Significant heart disease or impairment of cardiac function
  8. Fluid accumulating in the third space, such as pericardial effusion, pleural effusion and peritoneal effusion that remains uncontrolled by aspiration or other treatment
  9. Known allergy to drugs or excipients, known severe allergic reaction to any of the PD-1 monoclonal antibodies
  10. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

West China Hospital, Sichuan University

Chengdu, Sichuan, China, 610041

Actively Recruiting

Loading map...

Research Team

R

Ren Luo, MD

CONTACT

L

Li Li, BA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here